Every 10-Q that YUBO INTL BIOTECH LTD A (YBGJ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow YBGJ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YBGJ filings page.
Yubo International Biotech Limited reported no revenue for the three and six months ended June 30, 2026, reflecting that its China-based VIE, Yubo Beijing, has not generated sales during the period. Operating expenses were $528,135 for the first half of 2026, leading to a consolidated net loss of $563,747, slightly lower than the prior-year period loss.
Total assets were $672,272, including cash of $11,989, versus total current liabilities of $3,327,598, resulting in a shareholders’ deficit of $2,622,591. The company discloses substantial doubt about its ability to continue as a going concern, citing recurring losses, negative working capital of $2,744,500, and dependence on related-party financing and a financial support letter from a major shareholder. Operations are conducted in China through a variable interest entity structure, which the company notes carries significant PRC regulatory and enforceability risks that could materially affect the value of its Class A common stock.
Yubo International Biotech Limited reported no revenue for the quarter ended March 31, 2026 and continued to incur operating expenses as it develops its China-based stem cell and health products business through a variable interest entity structure.
The company recorded a net loss of $295,026, an improvement from a loss of $467,318 a year earlier, driven mainly by lower occupancy and operating costs. Cash stood at $10,382 and total assets were $709,872, against total liabilities of $3,019,451, resulting in a shareholders’ deficit of $2,309,579.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing negative working capital of $2,421,628 and ongoing losses. Operations are funded largely by related-party advances and customer/distributor prepayments, while the U.S. holding company relies on contractual control, rather than ownership, of its Chinese operating entity, which introduces additional legal and regulatory risks.
Yubo International Biotech Limited reported its quarterly results for the period ended September 30, 2025. The company generated no revenue and recorded a net loss of $310,152 for the quarter and $902,288 for the nine months. Operating expenses were $310,134 in the quarter, reflecting spending on compensation, occupancy, and depreciation.
On the balance sheet, cash was $10,926, total assets were $953,211, and total liabilities were $2,555,316, resulting in a shareholders’ deficit of $1,602,105. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing a working capital deficit of $1,905,753. During the quarter, the company issued 50,600,343 Class A shares at $0.05 per share to FlyDragon and ChinaOne, settling $2,530,000 of shareholder loans. Shares outstanding as of November 13, 2025 were 170,416,343 Class A and 4,447 Class B.
The company operates in China through a VIE structure (Yubo Beijing). Investors in Class A shares do not hold equity in the PRC operating entities, and the filing highlights risks that PRC authorities could disallow the contractual arrangements.